Evidence map›Paper›PMID 30882919›Full record

Observational studyTransfusion2019

Therapeutic impact of red blood cell transfusion on anemic outpatients: the RETRO study.

Elizabeth St Lezin, Matthew S Karafin, Roberta Bruhn, Dhuly Chowdhury, Lirong Qu, Walter Bialkowski, Scott Merenda, Pamela D'Andrea, Anne-Lyne McCalla, Lisa Anderson and 11 more

Open access · greenAbstract readMulticenter StudyObservational Study
In one paragraph

Observational study in Transfusion, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 34 citations in OpenAlex.

  1. Trial
  2. Observational
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Outpatient transfusions for myelodysplastic syndromes.Hematology. American Society of Hematology. Education Program · 2020
    Review
  11. Observational
  12. Early and sustained improvement in fatigue-related quality of life following red blood cell transfusion in outpatients.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2020
    Article
  13. Pretreatment hemoglobin level as a prognostic factor in patients with locally advanced head and neck squamous cell carcinoma.Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

21 authors at 10 institutions in 2 countries.

Elizabeth St LezinDepartment of Laboratory Medicine, University of California San Francisco, San Francisco, California.ORCID 0000-0001-6191-3418
Matthew S KarafinMedical Sciences Institute (MSI), BloodCenter of Wisconsin, Milwaukee, Wisconsin.ORCID 0000-0001-7533-6842
Roberta BruhnDepartment of Laboratory Medicine, University of California San Francisco, San Francisco, California.
Dhuly ChowdhuryRTI International, Rockville, Maryland.
Lirong QuUniversity of Pittsburgh, Pittsburgh, Pennsylvania.
Walter BialkowskiMedical Sciences Institute (MSI), BloodCenter of Wisconsin, Milwaukee, Wisconsin.
Scott MerendaYale Medical School, New Haven, Connecticut.
Pamela D'AndreaVitalant, Pittsburgh, Pennsylvania.
Anne-Lyne McCallaRTI International, Research Triangle Park, North Carolina.
Lisa AndersonMedical Sciences Institute (MSI), BloodCenter of Wisconsin, Milwaukee, Wisconsin.
Sheila M KeatingVitalant Research Institute, San Francisco, California.
Mars StoneVitalant Research Institute, San Francisco, California.
Edward L SnyderYale Medical School, New Haven, Connecticut.
Donald BrambillaRTI International, Rockville, Maryland.
Edward L MurphyDepartment of Laboratory Medicine, University of California San Francisco, San Francisco, California.
Philip J NorrisDepartment of Laboratory Medicine, University of California San Francisco, San Francisco, California.
Joan F HiltonDepartment of Laboratory Medicine, University of California San Francisco, San Francisco, California.
Bryan R SpencerAmerican Red Cross, Dedham, Massachusetts.
Steven KleinmanUniversity of British Columbia, Victoria, British Columbia, Canada.
Jeffrey L CarsonRutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey.
NHLBI Recipient Epidemiology and Donor Evaluation Study (REDS)-III Program
University of California, San Francisco · USRTI International · USVersiti Blood Center of Wisconsin · USPacific Research Institute · USYale University · USAmerican Red Cross · USRutgers, The State University of New Jersey · USUniversity of British Columbia · CAUniversity of Pittsburgh · USVitalant · US

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
NCATS NIH HHS UL1 TR001863NHLBI NIH HHS HHSN268201100001INHLBI NIH HHS HHSN 2682011-00001l to -00009lNHLBI NIH HHS HHSN268201100002INHLBI NIH HHS HHSN268201100004INHLBI NIH HHS HHSN268201100005INHLBI NIH HHS HHSN268201100007INHLBI NIH HHS HHSN268201100008INHLBI NIH HHS HHSN268201100009I
6 · The paper itself

Abstract

backgroundPatients with cancer or other diagnoses associated with chronic anemia often receive red blood cell (RBC) transfusion as outpatients, but the effect of transfusion on functional status is not well demonstrated. STUDY DESIGN AND

methodsTo estimate the effect of transfusion on functional status and quality of life, we measured 6-minute walk test distance and fatigue- and dyspnea-related quality-of-life scores before and 1 week after RBC transfusion in 208 outpatients age ≥50 with at least one benign or malignant hematology/oncology diagnosis. To account for potential confounding effects of cancer treatment, patients were classified into two groups based on cancer treatment within 4 weeks of the study transfusion. Minimum clinically important improvements over baseline were 20 meters in walk test distance, 3 points in fatigue score, and 2 points in dyspnea score.

resultsThe median improvement in unadjusted walk test distance was 20 meters overall and 30 meters in patients not receiving recent cancer treatment. Fatigue scores improved overall by a median of 3 points and by 4 points in patients without cancer treatment. There was no clinically important change in dyspnea scores. In multiple linear regression analysis, patients who maintained hemoglobin (Hb) levels of 8 g/dL or greater at 1 week posttransfusion, who had not received recent cancer treatment, and who did not require hospitalization during the study showed clinically important increases in mean walk test distance.

conclusionsRed blood cell transfusion is associated with a modest, but clinically important improvement in walk test distance and fatigue score outcomes in adult hematology/oncology outpatients.

Indexed as

Erythrocyte TransfusionAgedAmbulatory CareAnemiaDyspneaExercise TestFatigueFemaleHospitalizationHumansMaleMiddle AgedProspective StudiesQuality of LifeTreatment Outcome

Identifiers

PMID30882919
PMCPMC6548575
OpenAlexW2921701514

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.